TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05057754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heating
Description: A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercising
Description: Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Typing
Description: All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using a mouse
Description: Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking
Description: Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
Study: NCT05868499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG34217
Description: Single infusion
Study: NCT05015972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTA30X UCAR-T injection
Description: CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
Study: NCT05574998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (Endostar)
Description: The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed.
Study: NCT05008614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block group
Description: Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia group
Description: Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)
Study: NCT04938817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coformulation pembrolizumab/quavonlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coformulation pembrolizumab/quavonlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coformulation pembrolizumab/quavonlimab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coformulation favezelimab/pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R-DXd
Description: IV Infusion
Study: NCT06339905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonic Activation with EndoActivator
Description: sonic activation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Needle Irrigation
Description: control group
Study: NCT06561932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiSE CRT System
Description: The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
Study: NCT06312722

Intervention type: DEVICE
Group type: OTHER
Intervention: Optilume® BPH Catheter System
Description: The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
Study: NCT05540990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted gait training
Description: 15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
Study: NCT05636826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atherolive-drug
Description: The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Atherolive
Description: The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
Study: NCT05138172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced Air Heating Temperature control Twinwarm II
Description: For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Forced Air Heating Temperature control Twinwarm II
Description: For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models.
Study: NCT02811133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: Subjects will receive inositol
Study: NCT05120817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal intervention
Description: Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social intervention
Description: Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal + Social intervention
Description: Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
Study: NCT04579848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Tablets
Description: Methotrexate 2.5mg oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid 1 MG
Description: Folic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid 1 MG
Description: Folic acid
Study: NCT06035432

Intervention type: OTHER
Intervention: Bluesky software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.

Intervention type: OTHER
Intervention: 3D slicer software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.

Intervention type: OTHER
Intervention: OnDemand software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
Study: NCT06374095

Intervention type: DRUG
Intervention: RATG
Description: Thymoglobulin, Genzyme corporation, Italy.
Study: NCT06035432

Intervention type: OTHER
Intervention: Mimics software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
Study: NCT05858736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI-061
Description: A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
Study: NCT05948033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70-targeting CAR-T cells
Description: Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
Study: NCT06444165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab Pen
Description: Injected into a practice pad.
Study: NCT06574191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Diclofenac gel 1%
Description: Topical NSAID
Study: NCT05293002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorer Iliac Stent System
Description: Not applicable (only one intervention)
Study: NCT05818930

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: REMI
Description: Diagnostic monitoring
Study: NCT06374095

Intervention type: DRUG
Intervention: Basiliximab
Description: Simulect, Novartis, Italy.

Intervention type: DRUG
Intervention: Basiliximab
Description: Simulect, Novartis, Italy.
Study: NCT05798156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
Study: NCT05730764

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making
Description: With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinicians follow a routine protocol
Description: Treatment is performed by the clinician according to the usual protocol.
Study: NCT05798156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
Study: NCT06271538

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Skal Pro
Description: One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS
Study: NCT04648046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Non-ablative conditioning with cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Non-ablative conditioning with cyclophosphamide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVgp120duoCAR-T cells, low dose
Description: A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVgp120duoCAR-T cells, low dose
Description: A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVgp120duoCAR-T cells, high dose
Description: A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.
Study: NCT05291351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crackers made with whole, coarse, or fine pea and/or wheat flour
Description: Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crackers made with whole, coarse, or fine lentil and/or wheat flour
Description: Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
Study: NCT06271538

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
Study: NCT06101563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early ureteroscopy
Description: Patients will be managed by ureteroscopic lithotripsy 7 days after drainage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Ureteroscopy
Description: Patients will be managed by ureteroscopic lithotripsy 14-21 days after drainage.
Study: NCT04648046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption
Description: HIV antiretroviral therapy medications will be paused.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption
Description: HIV antiretroviral therapy medications will be paused.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption
Description: HIV antiretroviral therapy medications will be paused.
Study: NCT04088188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Given PO
Study: NCT05211986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMM01-STEM
Description: IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMM01-STEM
Description: IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
Study: NCT06226987

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-DOTATATE PET/MRI
Description: PET/MRI scanning
Study: NCT05628727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
Study: NCT05211986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMM01-STEM
Description: IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
Study: NCT05181462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadunolimab
Description: Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadunolimab
Description: Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.
Study: NCT06302543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow cells injection
Description: under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
Study: NCT05733390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP541
Description: Oral suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT05966792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Description: Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
Study: NCT04871282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL102
Description: AL102 is an inhibitor of gamma secretase-mediated Notch signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL102
Description: AL102 is an inhibitor of gamma secretase-mediated Notch signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL102
Description: AL102 is an inhibitor of gamma secretase-mediated Notch signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL102
Description: AL102 is an inhibitor of gamma secretase-mediated Notch signaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL102
Description: AL102 is an inhibitor of gamma secretase-mediated Notch signaling.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AL102
Study: NCT05291351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Porridge made with oat flour
Description: Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.